BR112012008330B1 - Compostos quinazolinas, suas composições farmacêuticas e seus usos - Google Patents

Compostos quinazolinas, suas composições farmacêuticas e seus usos Download PDF

Info

Publication number
BR112012008330B1
BR112012008330B1 BR112012008330-9A BR112012008330A BR112012008330B1 BR 112012008330 B1 BR112012008330 B1 BR 112012008330B1 BR 112012008330 A BR112012008330 A BR 112012008330A BR 112012008330 B1 BR112012008330 B1 BR 112012008330B1
Authority
BR
Brazil
Prior art keywords
alkyl
heteroaryl
heterocyclyl
cycloalkyl
aryl
Prior art date
Application number
BR112012008330-9A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112012008330A2 (pt
Inventor
James A. Johnson
John Lloyd
Healther Finlay
Ji Jiang
James Neels
Abhisek Banerjee
Ashokkumar Adisechan
Naveen Kumar Dhondi
Prashantha Gunaga
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of BR112012008330A2 publication Critical patent/BR112012008330A2/pt
Publication of BR112012008330B1 publication Critical patent/BR112012008330B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Catching Or Destruction (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR112012008330-9A 2009-09-03 2010-09-01 Compostos quinazolinas, suas composições farmacêuticas e seus usos BR112012008330B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23945209P 2009-09-03 2009-09-03
US61/239,452 2009-09-03
PCT/US2010/047430 WO2011028741A1 (en) 2009-09-03 2010-09-01 Quinazolines as potassium ion channel inhibitors

Publications (2)

Publication Number Publication Date
BR112012008330A2 BR112012008330A2 (pt) 2021-02-17
BR112012008330B1 true BR112012008330B1 (pt) 2022-03-22

Family

ID=42942118

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012008330-9A BR112012008330B1 (pt) 2009-09-03 2010-09-01 Compostos quinazolinas, suas composições farmacêuticas e seus usos

Country Status (32)

Country Link
US (9) US8575184B2 (enExample)
EP (3) EP3575288B1 (enExample)
JP (2) JP5643312B2 (enExample)
KR (1) KR101698631B1 (enExample)
CN (1) CN102753535B (enExample)
AR (1) AR078326A1 (enExample)
AU (1) AU2010289641B2 (enExample)
BR (1) BR112012008330B1 (enExample)
CA (1) CA2772642C (enExample)
CL (1) CL2012000583A1 (enExample)
CO (1) CO6511220A2 (enExample)
CY (2) CY1118488T1 (enExample)
DK (2) DK3575288T3 (enExample)
EA (1) EA021113B1 (enExample)
ES (3) ES2900504T3 (enExample)
HR (2) HRP20161669T1 (enExample)
HU (2) HUE032983T2 (enExample)
IL (1) IL218169A (enExample)
LT (2) LT2473487T (enExample)
MX (1) MX2012002099A (enExample)
MY (1) MY160243A (enExample)
NZ (1) NZ598516A (enExample)
PE (1) PE20121153A1 (enExample)
PL (2) PL2473487T3 (enExample)
PT (2) PT3575288T (enExample)
SG (1) SG178592A1 (enExample)
SI (2) SI2473487T1 (enExample)
SM (3) SMT201700026T1 (enExample)
TN (1) TN2012000063A1 (enExample)
TW (1) TWI488851B (enExample)
WO (1) WO2011028741A1 (enExample)
ZA (1) ZA201202383B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH068949B2 (ja) 1985-09-20 1994-02-02 富士写真フイルム株式会社 ハロゲン化銀カラ−写真感光材料
ES2900504T3 (es) * 2009-09-03 2022-03-17 Bristol Myers Squibb Co Quinazolinas como inhibidores de los canales iónicos de potasio
AR079814A1 (es) * 2009-12-31 2012-02-22 Otsuka Pharma Co Ltd Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
KR20140048216A (ko) * 2011-06-29 2014-04-23 오츠카 세이야쿠 가부시키가이샤 치료 화합물로서의 퀴나졸린 및 관련된 사용 방법
JP6121658B2 (ja) * 2011-06-29 2017-04-26 大塚製薬株式会社 治療用化合物、及び関連する使用の方法
CN103360382B (zh) * 2012-03-26 2016-04-27 中国科学院福建物质结构研究所 喹唑啉衍生物及其用途
SI2858987T1 (en) * 2012-06-11 2018-06-29 Bristol-Myers Squibb Company PREPARATION OF 5-PHENYL-4- (PYRIDIN-2-ILLETHYLAMINO) -CHUINAZOLIN-2-YL) -PIRIDIN-3-SULPHONAMIDE PHOSPHORAMIDIC ACID
WO2014133059A1 (ja) 2013-02-28 2014-09-04 武田薬品工業株式会社 スルホニルクロライド化合物の製造法
US9242966B2 (en) 2013-03-11 2016-01-26 Bristol-Myers Squibb Company Phthalazines as potassium ion channel inhibitors
EP2970199A1 (en) 2013-03-11 2016-01-20 Bristol-Myers Squibb Company Isoquinolines as potassium ion channel inhibitors
JP6386527B2 (ja) * 2013-03-11 2018-09-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ カリウムイオンチャネル阻害剤としてのピロロピリダジン
EP2970294B1 (en) * 2013-03-11 2016-12-28 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
US9050345B2 (en) * 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
BR112016008406B1 (pt) * 2013-10-17 2021-02-23 Sumitomo Chemical Company, Limited composto de tetrazolinona e aplicação do mesmo
CA2951784C (en) 2014-06-10 2022-05-31 Ube Industries, Ltd. N-substituted sulfonamide compound and method for producing same
CN106458903B (zh) 2014-06-10 2021-02-05 宇部兴产株式会社 杂芳族磺酰胺化合物的制造方法
US10774072B2 (en) 2014-06-10 2020-09-15 Ube Industries, Ltd. Crystal of N-substituted sulfonamide compound
CA2969839A1 (en) * 2014-12-05 2016-06-09 Subramaniam Ananthan Heterocyclic compounds as biogenic amine transport modulators
EP3226868A4 (en) 2014-12-05 2018-08-15 Subramaniam Ananthan Novel quinazolines as biogenic amine transport modulators
CN107848974A (zh) * 2015-06-10 2018-03-27 拜耳制药股份公司 芳族磺酰胺衍生物
HRP20201746T1 (hr) * 2016-05-03 2020-12-25 Bayer Pharma Aktiengesellschaft Aromatski derivati sulfonamida
CN106432067B (zh) * 2016-09-18 2019-04-19 北京天弘天达医药科技有限公司 一种3-吡啶磺酰氯的绿色化学合成方法
EP3700891A1 (en) * 2017-10-29 2020-09-02 Bayer Aktiengesellschaft Aromatic sulfonamide derivatives for the treatment of ischemic stroke
EP3820861A1 (en) * 2018-04-20 2021-05-19 Bayer Aktiengesellschaft Heteroaryl-triazole and heteroaryl-tetrazole compounds as pesticides
EP3972963A1 (en) 2019-05-21 2022-03-30 Bayer Aktiengesellschaft Identification and use of kras inhibitors
CN116323623B (zh) 2020-09-18 2025-09-26 拜耳公司 作为SOS1抑制剂的吡啶并[2,3-d]嘧啶-4-胺
EP4074317A1 (en) 2021-04-14 2022-10-19 Bayer AG Phosphorus derivatives as novel sos1 inhibitors
WO2023212181A1 (en) * 2022-04-28 2023-11-02 University Of Miami Compounds for proliferative disorders
WO2024056782A1 (en) 2022-09-16 2024-03-21 Bayer Aktiengesellschaft Sulfone-substituted pyrido[3,4-d]pyrimidine derivatives for the treatment of cancer
CN120112538A (zh) 2022-10-13 2025-06-06 拜耳公司 Sos1抑制剂
WO2025202022A1 (en) 2024-03-27 2025-10-02 Bayer Aktiengesellschaft Anticancer macrocyclic quinazoline-based inhibitors of the ineraction between ras and sos1

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3843791A (en) 1973-01-11 1974-10-22 Pfizer Method of killing insects with quinazolinones and quinazoline-thiones
DK0498722T3 (da) 1991-02-07 1998-03-09 Roussel Uclaf Nye bicycliske nitrogenforbindelser substitueret med en benzylgruppe, fremgangsmåde til deres fremstilling, de opnåede nye intermediærer, deres anvendelse som lægemidler og de pharmaceutiske præparater som de indgår i
US6645969B1 (en) 1991-05-10 2003-11-11 Aventis Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
JP2657760B2 (ja) 1992-07-15 1997-09-24 小野薬品工業株式会社 ４−アミノキナゾリン誘導体およびそれを含有する医薬品
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
EP0655456B1 (en) 1993-06-17 2000-09-06 Otsuka Pharmaceutical Factory, Inc. Phosphonic diester derivative
GB9314884D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Tricyclic derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US5679683A (en) 1994-01-25 1997-10-21 Warner-Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
JPH083144A (ja) 1994-06-21 1996-01-09 Chugai Pharmaceut Co Ltd キナゾリン及びキノリン誘導体
TW414798B (en) 1994-09-07 2000-12-11 Thomae Gmbh Dr K Pyrimido (5,4-d) pyrimidines, medicaments comprising these compounds, their use and processes for their preparation
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB9424233D0 (en) 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
AU7692996A (en) * 1995-12-01 1997-06-27 Ciba-Geigy Ag Receptor antagonists
NZ325248A (en) * 1995-12-23 1999-09-29 Pfizer Res & Dev Quinoline and quinazoline compounds useful in therapy
EP0912559B1 (en) 1996-07-13 2002-11-06 Glaxo Group Limited Fused heterocyclic compounds as protein tyrosine kinase inhibitors
AU7890598A (en) 1996-12-27 1998-07-31 Yoshitomi Pharmaceutical Industries, Ltd. Fused pyrimidine compounds and medicinal use thereof
JP4713698B2 (ja) 1997-03-05 2011-06-29 スージェン， インク． 疎水性薬剤の処方
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
AU7301000A (en) 1999-09-21 2001-04-24 Astrazeneca Ab Quinazoline derivatives and their use as pharmaceuticals
OA12050A (en) * 1999-09-30 2006-05-02 Neurogen Corp Certain alkylene diamine-substituted heterocycles.
US6605615B2 (en) 2000-03-01 2003-08-12 Tularik Inc. Hydrazones and analogs as cholesterol lowering agents
WO2001083456A1 (en) 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Condensed heteroaryl derivatives
PL359918A1 (en) 2000-09-20 2004-09-06 Merck Patent Gmbh 4-amino-quinazolines
CN1474815A (zh) 2000-09-20 2004-02-11 Ĭ��ר���ɷ����޹�˾ 4-氨基-喹唑啉
WO2002062767A1 (en) 2001-02-07 2002-08-15 Sumitomo Pharmaceuticals Company, Limited Novel quinazoline derivatives
WO2002092579A1 (en) 2001-05-14 2002-11-21 Astrazeneca Ab 4-anilinoquinazoline derivatives
US7829566B2 (en) 2001-09-17 2010-11-09 Werner Mederski 4-amino-quinazolines
US7645878B2 (en) 2002-03-22 2010-01-12 Bayer Healthcare Llc Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
WO2004017950A2 (en) 2002-08-22 2004-03-04 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
AU2003255482A1 (en) 2002-10-02 2004-04-23 Merck Patent Gmbh Use of 4 amino-quinazolines as anti cancer agents
WO2004030671A2 (en) 2002-10-02 2004-04-15 Merck Patent Gmbh Use of 4-amino-quinazolines as anti cancer agents
WO2004056812A1 (en) 2002-12-23 2004-07-08 Astrazeneca Ab 4- (pyridin-4-ylamino) -quinazoline derivatives as anti-tumor agents
WO2004056801A1 (en) 2002-12-23 2004-07-08 Astrazeneca Ab Quinazoline derivatives
WO2004069145A2 (en) 2003-02-07 2004-08-19 Dr. Reddy's Laboratories Ltd. Anticancer compounds, process for their preparation and pharmaceutical compositions containing them
CL2004000409A1 (es) * 2003-03-03 2005-01-07 Vertex Pharma Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu
ZA200507979B (en) * 2003-03-03 2007-03-28 Vertex Pharma Inc Quinazolines useful as modulators of ion channels
US7713983B2 (en) 2003-03-03 2010-05-11 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
EP1611109A4 (en) 2003-03-31 2009-06-24 Taisho Pharmaceutical Co Ltd NOVEL QUINAZOLINE DERIVATIVES AND THEIR THERAPEUTIC USE
SI1641803T1 (sl) 2003-06-11 2009-08-31 Xention Ltd Tienopirimidinski derivati kot inhibitorji kalijevih kanalov
BRPI0411514A (pt) 2003-06-20 2006-08-01 Coley Pharm Gmbh antagonistas de receptor toll-like de molécula pequena
CN1984660B (zh) 2003-07-03 2010-12-15 美瑞德生物工程公司 作为天冬氨酸特异性半胱氨酸蛋白酶活化剂和细胞程序死亡诱导剂的4-芳基氨基-喹唑啉
JP4719681B2 (ja) * 2003-09-23 2011-07-06 メルク・シャープ・エンド・ドーム・コーポレイション キナゾリンカリウムチャネル阻害剤
JP2007510642A (ja) 2003-11-03 2007-04-26 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 中枢神経系障害の治療のための新規ノルエピネフリン再取込み阻害薬
WO2005080377A1 (ja) 2004-02-20 2005-09-01 Kirin Beer Kabushiki Kaisha TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物
WO2005087742A1 (en) 2004-03-08 2005-09-22 Exelixis, Inc. Metabolic kinase modulators and methods of use as pesticides
WO2005087749A1 (ja) 2004-03-15 2005-09-22 Kyowa Hakko Kogyo Co., Ltd. ２−アミノキナゾリン誘導体
AU2005252440A1 (en) 2004-06-10 2005-12-22 Xention Discovery Limited Furanopyrimidine compounds effective as potassium channel inhibitors
WO2006004722A2 (en) 2004-06-30 2006-01-12 Biomol Research Laboratories, Inc. Compositions and methods for selectively activating human sirtuins
CN101031551A (zh) 2004-07-06 2007-09-05 安吉永生物制药公司 针对癌症治疗的肝细胞生长因子/c－met活性的喹唑啉调节剂
EP1879899B1 (en) 2004-12-09 2010-08-04 Xention Limited Thienopyridine derivatives as potassium channel inhibitors
WO2006071095A1 (en) 2004-12-31 2006-07-06 Sk Chemicals Co., Ltd. Quinazoline derivatives for the treatment and prevention of diabetes and obesity
AU2006214138A1 (en) 2005-02-18 2006-08-24 Novartis Vaccines And Diagnostics Inc. Antiangiogenic agents with aldesleukin
US8252806B2 (en) 2005-03-14 2012-08-28 Neurosearch A/S Potassium channel modulating agents and their medical use
CN101180299B (zh) 2005-03-23 2010-12-15 弗·哈夫曼-拉罗切有限公司 作为mglur2拮抗剂的乙炔基-吡唑并嘧啶衍生物
ES2369282T3 (es) 2005-03-25 2011-11-29 Tibotec Pharmaceuticals Inhibidores heterobicíclicos de vhc.
MX2007011850A (es) 2005-03-25 2007-10-03 Tibotec Pharm Ltd Inhibidores heterobiciclicos de virus de hepatitis c.
JP5079500B2 (ja) 2005-04-28 2012-11-21 協和発酵キリン株式会社 ２−アミノキナゾリン誘導体
EP1901744A2 (en) 2005-06-28 2008-03-26 Bausch & Lomb Incorporated Preparations comprising arylazine substituted with a carbonylic moiety to increase the activity of gelatinase a in ocular cells
GB0525164D0 (en) 2005-12-09 2006-01-18 Xention Discovery Ltd Compounds
EP1966184B1 (en) 2005-12-20 2010-08-25 NeuroSearch A/S Pyridinyl-quinazoline derivatives and their medical use
US20070197509A1 (en) 2005-12-21 2007-08-23 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
DE102006012251A1 (de) 2006-03-15 2007-11-08 Grünenthal GmbH Substituierte 4-Amino-chinazolin-Derivate und ihre Verwendung zur Herstellung von Arzneimitteln
US20100016293A1 (en) 2006-07-03 2010-01-21 Rogier Adriaan Smits Quinazolines and Related Heterocyclic Compounds, and Their Therapeutic Use
CA2661307C (en) 2006-08-22 2016-07-19 Technion Research And Development Foundation Ltd. Heterocyclic derivatives binding to the peripheral-type benzodiazepine receptor (pbr)
US20100173332A1 (en) 2006-09-07 2010-07-08 Auckland Uniservices Limited Method for the Fluorescent Detection of Nitroreductase Activity Using Nitro-Substituted Aromatic Compounds
WO2008045529A1 (en) 2006-10-12 2008-04-17 Serenex, Inc. Purine and pyrimidine derivatives for treatment of cancer and inflammatory diseases
US8039505B2 (en) 2007-04-11 2011-10-18 University Of Utah Research Foundation Compounds for modulating T-cells
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
WO2008150827A1 (en) 2007-05-29 2008-12-11 Smithkline Beecham Corporation Naphthyridine, derivatives as p13 kinase inhibitors
US9603848B2 (en) 2007-06-08 2017-03-28 Senomyx, Inc. Modulation of chemosensory receptors and ligands associated therewith
WO2009006141A2 (en) 2007-07-05 2009-01-08 Bausch & Lomb Incorporated Authority to read as follows: compositions and methods for treating or controlling infections of the eye a sequelae thereof
CN101575333B (zh) 2008-05-09 2011-06-22 和记黄埔医药（上海）有限公司 一种喹唑啉衍生物及其医药用途
US7829574B2 (en) 2008-05-09 2010-11-09 Hutchison Medipharma Enterprises Limited Substituted quinazoline compounds and their use in treating angiogenesis-related diseases
AU2009249106A1 (en) 2008-05-21 2009-11-26 Genentech, Inc. Arylsulfonamide compounds, compositions and methods of use
ES2900504T3 (es) 2009-09-03 2022-03-17 Bristol Myers Squibb Co Quinazolinas como inhibidores de los canales iónicos de potasio
WO2011029054A1 (en) 2009-09-04 2011-03-10 The Regents Of The University Of Michigan Compositions and methods for treatment of leukemia
AR079814A1 (es) 2009-12-31 2012-02-22 Otsuka Pharma Co Ltd Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos

Also Published As

Publication number Publication date
US20200255407A1 (en) 2020-08-13
DK2473487T3 (en) 2017-02-06
CA2772642C (en) 2017-08-29
JP5950978B2 (ja) 2016-07-13
CO6511220A2 (es) 2012-08-31
LT2473487T (lt) 2017-01-10
EP3124475A1 (en) 2017-02-01
PL2473487T3 (pl) 2017-07-31
PT2473487T (pt) 2017-01-04
TWI488851B (zh) 2015-06-21
EA021113B1 (ru) 2015-04-30
CN102753535A (zh) 2012-10-24
WO2011028741A1 (en) 2011-03-10
CY1118488T1 (el) 2017-07-12
DK3575288T3 (da) 2021-12-20
ES2900504T3 (es) 2022-03-17
PE20121153A1 (es) 2012-08-27
IL218169A0 (en) 2012-07-31
AU2010289641B2 (en) 2015-05-07
HRP20211973T1 (hr) 2022-03-18
ES2750598T3 (es) 2020-03-26
JP2013503875A (ja) 2013-02-04
IL218169A (en) 2015-11-30
KR20120125978A (ko) 2012-11-19
HRP20161669T1 (hr) 2017-02-24
ZA201202383B (en) 2013-09-25
US20230322726A1 (en) 2023-10-12
CY1125021T1 (el) 2023-03-24
SG178592A1 (en) 2012-04-27
AU2010289641A1 (en) 2012-03-22
CL2012000583A1 (es) 2012-08-31
SI2473487T1 (sl) 2017-02-28
US9822096B2 (en) 2017-11-21
AR078326A1 (es) 2011-11-02
US11008306B2 (en) 2021-05-18
US8575184B2 (en) 2013-11-05
NZ598516A (en) 2013-02-22
LT3575288T (lt) 2021-12-10
SI3575288T1 (sl) 2022-01-31
US20220324836A1 (en) 2022-10-13
SMT201700026T1 (it) 2017-03-08
US10676460B2 (en) 2020-06-09
US20120232068A1 (en) 2012-09-13
EP3575288B1 (en) 2021-10-27
US9458114B2 (en) 2016-10-04
CA2772642A1 (en) 2011-03-10
CN102753535B (zh) 2015-03-25
HUE057433T2 (hu) 2022-05-28
EP2473487A1 (en) 2012-07-11
US20160362396A1 (en) 2016-12-15
US20190144426A1 (en) 2019-05-16
SMT202100717T1 (it) 2022-01-10
MY160243A (en) 2017-02-28
PT3575288T (pt) 2021-12-09
HUE032983T2 (en) 2017-11-28
SMT201700026B (it) 2017-03-08
TW201113267A (en) 2011-04-16
US20140031345A1 (en) 2014-01-30
EP2473487B1 (en) 2016-10-26
MX2012002099A (es) 2012-04-11
TN2012000063A1 (en) 2013-09-19
JP5643312B2 (ja) 2014-12-17
BR112012008330A2 (pt) 2021-02-17
JP2015057410A (ja) 2015-03-26
EA201270378A1 (ru) 2012-07-30
EP3575288A1 (en) 2019-12-04
EP3124475B1 (en) 2019-08-07
ES2609335T3 (es) 2017-04-19
US20250230144A1 (en) 2025-07-17
US20180030034A1 (en) 2018-02-01
PL3575288T3 (pl) 2022-01-24
KR101698631B1 (ko) 2017-01-20
US10214511B2 (en) 2019-02-26

Similar Documents

Publication Publication Date Title
US11008306B2 (en) Quinazolines as potassium ion channel inhibitors
US9242966B2 (en) Phthalazines as potassium ion channel inhibitors
CN105008366B (zh) 作为钾离子通道抑制剂的吡咯并哒嗪类化合物
HK40018229A (en) Quinazolines as potassium ion channel inhibitors
HK40018229B (en) Quinazolines as potassium ion channel inhibitors

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/09/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.